Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by CNVCMon May 12, 2013 11:50am
71 Views
Post# 21395630

Similar growth rates

Similar growth rates

Same growth rate. One started catching the market's attention first. Should result in the same outcome.

AVO.T earnings per share latest quarter $0.07. PE ratio 71
 

  • Revenue was $32-million, an increase of 80 per cent over 2012 first quarter revenue of $17.8-million.
  • EBITDA (earnings before interest, taxes, depreciation and amortization) was $5.1-million, a 319-per-cent improvement over 2012 first quarter EBITDA of $1.2-million.
  • Net income was $2.8-million, a 332-per-cent increase from net income of $600,000 in the first quarter of 2012.



    DND.T latest quarter earnings per share $0.06, PE ratio 24
  • Net revenue increased by 82 per cent over first-quarter 2012 to $3.3-million.
  • EBITDA (earnings before interest, taxes, depreciation and amortization) was $1.7-million against $300,00 in first-quarter 2012.
  • Net income was $1.5-million, or six cents per share, compared with net income of $100,000, or one cent per share, in first-quarter 2012.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities